

Table 1. Demographics, clinical presentation, laboratory findings, treatment and outcomes of multisystem inflammatory syndrome in adult (MIS-A) patients

	Patient 1	Patient 2	Patient 3	
<b>Demographics</b>				
Age, years, male sex	44	55	58	
Ethnicity	Chinese	Indian	Chinese	
Medical history	None	ESKD, IHD, mixed cardiomyopathy	HIV (on RAL + 3TC + ATV), poorly controlled DM (receiving metformin 850mg BD and linagliptin 5mg OM)	
<b>Clinical presentation</b>				
Onset after SARS-CoV-2 infection, days	29	62	12	
Duration of symptom onset to admission, days	4	2	2	
Initial symptoms	Fever, right-sided throat pain, syncope, vomiting, diarrhoea	Fever, abdominal pain	Abdominal pain, vomiting	
Maximal temperature, °C	40.8	39	39	
Clinical features	Fever, cardiomyopathy, hypotension, gastrointestinal (vomiting)	Fever, recurrent VT/VF collapse, hypotension, gastrointestinal (nausea, abdominal pain)	Fever, hypotension, AF, rash, gastrointestinal (vomiting, abdominal pain), acute kidney injury	
<b>Investigations</b>				
Laboratory tests	(Healthy reference)			
SARS-CoV-2 infection confirmed by	ART and RT-PCR (cycle threshold 16.23)	ART	ART	
Range of leucocyte count during hospitalisation, $\times 10^9/L$	4.0–9.6	7.0–23.4	7.5–17.0	10.3–18.3
Leucocyte count corresponding to follow-up immunological profile, $\times 10^9/L^a$		4.8	7.8	11.2
Range of lymphocyte count during hospitalisation, $\times 10^9/L$	1.10–6.60	0.44–2.02	0.36–3.84	0.45–4.65
Range of platelet count during hospitalisation, $\times 10^9/L$	150–360	172–1177	145–397	191–289
Platelet count corresponding to follow-up immunological profile, $\times 10^9/L^a$		306	311	245
Peak CRP, mg/L	<5	>380	131.1	229.5
CRP corresponding to follow-up immunological profile, mg/L <sup>a</sup>		2.8	21.9	5.4
Peak ferritin, $\mu g/L$	12–307	5367	4175	669
Ferritin corresponding to follow-up immunological profile, $\mu g/L^a$		704	613	22
LDH, U/L	270–550	448	1092	813

Table 1. Demographics, clinical presentation, laboratory findings, treatment and outcomes of multisystem inflammatory syndrome in adult (MIS-A) patients (Cont'd)

		Patient 1	Patient 2	Patient 3
<b>Immunological profile</b>				
Timing of initial test from onset of illness		12 days	29 days	11 days
IL-6, pg/mL	<2	74.1	177.8	109.6
IL-6 follow-up, <sup>a</sup> pg/mL		1.1	2.3	0.3
IL-10, pg/mL	<2	27.6	47.5	2.9
IL-10 follow-up, <sup>a</sup> pg/mL		1.9	1	1.2
IP-10, pg/mL	31.9 (23.2–42.6) <sup>b</sup>	3848.7	225	1989.9
IP-10 follow-up, <sup>a</sup> pg/mL		102.6	124.3	77.6
IL-18, pg/mL	138 (107–169) <sup>b</sup>	2601.9	1922.4	1360.1
IL-18 follow-up, <sup>a</sup> pg/mL		204.3	417.1	95.4
C5a, ng/mL	47.4 (32.1–53.4) <sup>b</sup>	79.91	111.4	28.5
C5a follow-up, <sup>a</sup> ng/mL,		32.6	42	29.5
ICAM-1, ng/mL	<95	187.8	355.9	231.1
ICAM-1 follow-up, <sup>a</sup> ng/mL		52.9	76.4	42.7
MCP-1, pg/mL	168.2 (134.2–196.6) <sup>b</sup>	380.7	1748.7	135.8
MCP-1 follow-up, <sup>a</sup> pg/mL		163.3	123.9	125.7
<b>Coagulation studies</b>				
Prothrombin time, seconds	11.7–14.0	16.1	17.8	12.5
Activated partial thromboplastin clotting time, seconds	27.0–27.0	49.2	33.1	34.2
Thrombin clotting time, seconds	15.0–18.0	N/A	15.9	17.4
D-dimer, µg/mL	<0.50	N/A	>4	>4
Fibrinogen, g/L	1.8–4.5	N/A	2.8	6.2
Anti-thrombin (%)	80–130	N/A	65	81
Protein S activity (%)	65–130	N/A	70	81
Protein C activity (%)	70–150	N/A	63	76
Factor V (%)	70–120	N/A	43	116
Factor VIII (%)	60–150	N/A	325	304
vWF:Ag (%)	56–160	N/A	>400	280
Ristocetin cofactor	47–148	N/A	>240	240
<b>Cardiac investigations</b>				
Transthoracic echocardiogram		EF 45%, mild global hypokinesia	EF 30%, regional wall motion abnormality consistent with multivessel disease	EF 60%, no RWMA or significant valvular dysfunction <sup>c</sup>
Others		CMR features met criteria for acute myocarditis	Coronary angiogram: patent RCA stent, minor coronary artery disease	N/A